Biotech Boulevard
Startups and Spinouts
GEN's Biotech Boulevard highlights new entrepreneurial biotech firms based all over the globe. These unique companies are developing breakthrough products that will expand and enhance the biotech industry.
Discover, invest, and collaborate with these industry leaders of tomorrow.
Explore Biotech Boulevard. It's paved with opportunities!
GEN's Biotech Boulevard
All  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z   0  1  2  3  4  5  6  7  8  9   
  • Helmedix

    Helmedix, a start-up company from the ithree institute at the University of Technology Sydney, is a biopharmaceutical company developing therapies for autoimmune diseases based on peptides derived from a helminth parasite. Helmedix will be managed as a virtual company, based in Sydney, with research contracted to Dr Donnelly’s team at the ithree institute.

  • Hepregen

    Hepregen's mission is to translate the value of its technology platform to improve the safety and efficacy of drugs in development with greater economic efficiency and significant impact on patients' lives. The company is focused on advancing and commercializing its microliver platform, HepatoPac™, into the drug-development pipeline of pharmaceutical and biotechnology companies. Hepregen's platform technology offers the potential to deliver a breakthrough technology for toxicity screening and a new platform for drug discovery.


  • HiberGene

    HiberGene is developing a molecular diagnostic test for meningitis which can be used to test for the presence of the two most common forms of the disease, Meningococcus and Pneumococca. The test uses a rapid isothermal amplification platform allowing accurate results to be delivered in less than forty minutes. The company intends to develop a range of tests for a number of infectious human diseases including healthcare associated infections and sexually transmitted Infections.

  • Hookipa Biotech

    Hookipa Biotech, founded in Vienna, Austria in summer 2011, develops a new class of innovative prophylactic and therapeutic vaccines. The Vaxwave® technology is a vaccine platform using a replication-defective viral vector for the prevention and treatment of multiple infectious diseases and cancer. The company currently focuses on the development of its lead vaccine candidate HB101 and plans to further industrialize the Vaxwave® technology and build a robust product pipeline. Hookipa has recently moved into its BSL2 facility at the Campus Vienna Biocenter.

© 2012 Genetic Engineering & Biotechnology News. All Rights Reserved.
Back to